Egypt’s National Strategy for Vaccine Manufacturing Localization (2024-2030)

In November 2024, Egypt officially launched its National Strategy for Vaccine Manufacturing Localization (2024–2030), marking a historic commitment to securing the country’s health sovereignty and building a robust, export-ready biological industry.

This strategy, anchored in Prime Ministerial Decree No. 719 (2024), designates the Egyptian Vaccine Manufacturers Alliance (EVMA) as its executive arm. EVMA operates under the guidance of the Unified Procurement Authority (UPA), in coordination with the Ministry of Health and Population and the Egyptian Drug Authority.

Strategic Goals

Short-term (by 2030): Localize 50% of Egypt’s vaccine production.
Medium-term (by 2035): Increase localization to 75%, deepen research partnerships, and secure WHO Prequalification for multiple vaccines.
Long-term (by 2040): Achieve complete self-sufficiency, expand exports by 50%, and strengthen Egypt’s role as a regional vaccine hub.

BY 2030

BY 2035

BY 2040

Key Pillars of the Strategy

Technology Transfer: Egypt is partnering with global vaccine developers to bring advanced manufacturing know-how to its local industry.
Long-term Contracts & Incentives: The strategy includes long-term procurement agreements and financial incentives — including tax relief — to stimulate private investment in vaccine production.
Regulatory Strength & Quality Assurance: EVMA will work with regulatory authorities and international partners to meet global quality standards and obtain WHO certification.
Regional Cooperation: Through EVMA, Egypt aims to contribute to African health resilience by aligning with continental mechanisms, expanding its export reach, and building manufacturing capacity across the continent.
Human Capital & Innovation: The strategy supports the development of a regional training center (EVMA-RCCN) to build skilled workforce capacity in biomanufacturing for both Egypt and Africa.

Strategic Impact

Health Security: Reducing dependence on imported vaccines strengthens Egypt’s ability to respond quickly to health emergencies.
Economic Sovereignty: Local manufacturing reduces import costs, supports high-value industrial jobs, and stimulates technology-driven growth.
Continental Leadership: By scaling local production and fostering export capacity, Egypt is positioning itself as a vaccine manufacturing hub for Africa, in alignment with broader continental health goals.
Sustainable Industrialization: The strategy aligns with Egypt’s long-term industrial development plans, contributing to its broader economic transformation.

Egypt’s national strategy for vaccine localization is more than an industrial policy — it is a strategic investment in the health, economic resilience, and continental leadership of the country. With EVMA as its operational instrument, the vision is clear: a self-reliant Egypt manufacturing high-quality vaccines for its people and for Africa.

Attachments

Download Egypt’s National Strategy for Vaccine Manufacturing Localization

National_Vaccine_Manufacturing_Localization_Strategy.pdf